Progyny (NASDAQ:PGNY) Releases FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 1.830-1.950 for the period, compared to the consensus EPS estimate of 1.550. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q1 2026 guidance to 0.420-0.450 EPS.

Progyny Price Performance

Progyny stock traded up $0.92 during mid-day trading on Thursday, reaching $22.25. 1,852,843 shares of the company traded hands, compared to its average volume of 1,438,952. Progyny has a 52-week low of $17.98 and a 52-week high of $28.75. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of 35.32, a P/E/G ratio of 1.31 and a beta of 0.96. The firm’s 50 day moving average price is $24.16 and its 200 day moving average price is $23.14.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, February 26th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.24). Progyny had a net margin of 4.46% and a return on equity of 10.71%. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, sell-side analysts anticipate that Progyny will post 0.6 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PGNY. Barclays initiated coverage on Progyny in a research report on Monday, December 8th. They issued an “overweight” rating and a $29.00 target price for the company. BTIG Research reiterated a “buy” rating on shares of Progyny in a report on Wednesday, January 21st. Citigroup raised Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Canaccord Genuity Group boosted their target price on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a report on Monday, November 17th. Finally, Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $29.80.

Institutional Investors Weigh In On Progyny

A number of institutional investors have recently made changes to their positions in PGNY. Caitong International Asset Management Co. Ltd bought a new position in shares of Progyny during the 4th quarter valued at $25,000. Canada Pension Plan Investment Board bought a new position in Progyny in the second quarter valued at about $77,000. Quarry LP lifted its holdings in Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after acquiring an additional 3,427 shares during the period. Tower Research Capital LLC TRC boosted its position in Progyny by 203.5% in the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after purchasing an additional 4,708 shares during the last quarter. Finally, Entropy Technologies LP purchased a new position in Progyny in the fourth quarter worth about $203,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.